Recruiting studies: Locally Advanced Lung Neuroendocrine Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230 A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Ot
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06505824 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116 Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242 Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Phase N/A · 1 location(s) · Mayo Clinic · NCT06075524 A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic S
Phase 1 · 1 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT07376707 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494 A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06066138 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626 A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381 EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285 Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520 Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumor
Phase 2 · 29 location(s) · National Cancer Institute (NCI) · NCT04665739

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.